Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
30 participants
OBSERVATIONAL
2025-10-15
2027-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Diaphragm Performance During Weaning From Mechanical Ventilation
NCT06203353
Diaphragmatic Rapid Shallow Breathing Index for Predicting Weaning Outcome From Mechanical Ventilation
NCT03561792
Randomized Study to Investigate the Safety and Performance of Diaphragm Stimulation Coupled With Mechanical Ventilation
NCT04457427
Diaphragmatic Ultrasound and Weaning After Lung Transplant.
NCT05670327
The Effect of External Diaphragmatic Pacemaker on the Patients With Chronic Cor Pulmonale
NCT02976324
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This prospective cohort study aims to evaluate the longitudinal impact of BiPAP treatment on diaphragm structure and function in patients with COPD and chronic hypercapnic respiratory failure. Eligible participants will be patients who are prescribed BiPAP therapy according to standard clinical indications. Diaphragm function will be assessed repeatedly using ultrasonography, which provides non-invasive and reliable measurements of diaphragm thickness at end-inspiration and end-expiration, thickening fraction (DTF), maximum contraction velocity, and maximum relaxation velocity. These measurements will be complemented by pulmonary function tests, respiratory muscle strength evaluations, and dyspnea assessment.
The primary outcome is the change in diaphragm ultrasound parameters (inspiratory thickness, expiratory thickness, thickening fraction, contraction velocity, and relaxation velocity) over the course of treatment. Early follow-up will occur at 6 weeks to assess short-term effects, while long-term follow-up at 12 months will provide insight into sustained adaptations to BiPAP therapy. Secondary outcomes include the frequency of hospital admissions and overall one-year survival.
By integrating functional, structural, and clinical outcomes, the study is expected to provide novel evidence on the role of non-invasive ventilation in modifying diaphragm performance. Findings may contribute to refining treatment strategies and optimizing long-term management of COPD patients with advanced respiratory failure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
copd patients
Patients diagnosed with chronic obstructive pulmonary disease (COPD) who have been prescribed BiPAP therapy by a physician. Participants will undergo diaphragmatic function evaluations with ultrasound at baseline, after 6 weeks of BiPAP usage, and after one year.
BIPAP
After BIPAP Prescribed By A Physician, Diaphragmatic Functions Will Be Evaluated With Ultrasound In The Early And Late Periods
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BIPAP
After BIPAP Prescribed By A Physician, Diaphragmatic Functions Will Be Evaluated With Ultrasound In The Early And Late Periods
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having a diagnosis of stable COPD for at least 1 year,
* Being in a stable phase (no acute exacerbation within the last 4 weeks),
* Meeting the GOLD 2025 A-B-E classification according to symptoms and exacerbation history,
* Having been initiated on BiPAP therapy with a clinical indication,
* Being willing to participate in the study and providing informed consent.
Exclusion Criteria
* Diaphragmatic paralysis,
* Neuromuscular and neurological diseases,
* Decompensated heart failure,
* Chest deformity,
* Acute exacerbation within the last month,
* Pneumothorax,
* Body mass index greater than 35 kg/m²,
* Long-term corticosteroid use,
* Chemotherapy,
* Active malignancy,
* Inability to cooperate,
* Thoracoabdominal surgery within the last 3 months.
40 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital
OTHER
Istanbul Demiroglu Bilim University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Reyhan Kaygusuz
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Reyhan Kaygusuz Benli, Asst Prof
Role: PRINCIPAL_INVESTIGATOR
Demiroglu Bilim University, Dept. of Physiotherapy and Rehabilitation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Demiroglu Bilim University, Department of Physiotherapy and Rehabilitation
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Reyhan Kaygusuz Benli Principal Investigator, Asst Prof
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Effect of BIPAP on diaphragm
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.